A number of other research analysts have also weighed in on MDSO. Wells Fargo & Co reissued a hold rating on shares of Medidata Solutions in a report on Thursday, June 13th. JPMorgan Chase & Co. raised shares of Medidata Solutions from an underweight rating to a neutral rating in a report on Wednesday, June 12th. SunTrust Banks raised their target price on shares of Medidata Solutions from $85.00 to $92.25 and gave the company a hold rating in a report on Thursday, June 13th. William Blair lowered shares of Medidata Solutions from an outperform rating to a market perform rating in a report on Wednesday, June 12th. Finally, Guggenheim lowered shares of Medidata Solutions from a buy rating to a neutral rating and set a $92.25 target price for the company. in a report on Wednesday, June 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $84.27.
MDSO stock opened at $91.83 on Friday. The firm has a fifty day moving average price of $91.52 and a 200 day moving average price of $87.07. Medidata Solutions has a fifty-two week low of $60.10 and a fifty-two week high of $98.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.56 and a current ratio of 2.56. The firm has a market cap of $5.74 billion, a PE ratio of 95.66, a price-to-earnings-growth ratio of 6.19 and a beta of 1.23.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Water Island Capital LLC bought a new stake in Medidata Solutions in the second quarter worth $23,126,000. Polar Asset Management Partners Inc. bought a new stake in Medidata Solutions in the second quarter worth $2,715,000. Treasurer of the State of North Carolina bought a new stake in Medidata Solutions in the second quarter worth $2,189,000. Nomura Holdings Inc. bought a new stake in Medidata Solutions in the second quarter worth $2,500,000. Finally, Maverick Capital Ltd. bought a new stake in Medidata Solutions in the second quarter worth $4,123,000. Institutional investors own 91.31% of the company’s stock.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Read More: What is the Fibonacci sequence?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.